# A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

> **NCT01610492** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Glomerulonephritis, Membranous

## Interventions

- **DRUG:** belimumab

## Key facts

- **NCT ID:** NCT01610492
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-01
- **Primary completion:** 2014-09-24
- **Final completion:** 2016-09-14
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610492, "A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01610492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*